Log In

New? Register Here

Acorda Therapeutics Inc

420 Saw Mill River Road

  • Main Phone: (914) 347-4300
  • Fax Number: (914) 347-4560
  • Date Founded: N/A
  • Employees: N/A
  • Testimonials: None Provided
  • Endorsements: None Provided
  • Announcements: 0


Acorda Therapeutics, Inc. (Acorda) is a commercial-stage biopharmaceutical company. The Company is engaged in the identification, development and commercialization of novel therapies that improve neurological function in people with multiple sclerosis (MS), spinal cord injury (SCI), and other disorders of the nervous system. Ampyra (dalfampridine) is an extended release tablet formulation of dalfampridine (4-aminopyridine, 4-AP). It also sells Zanaflex Capsules and Zanaflex tablets, which contain tizanidine hydrochloride, a short-acting drug for the management of spasticity. Ampyra is marketed as Fampyra outside the United States by Biogen Idec International GmbH (Biogen Idec). On February 6, 2012, the Company launched tizanidine hydrochloride capsules, an authorized generic version of Zanaflex Capsules under an agreement with Watson Pharma, Inc. In December 2012, the Company acquired Neuronex, Inc.


Not provided at this time


Not provided at this time


There are no company announcements at this time.

Company's Strengths and Specialties

There is no information provided at this time.